1. Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy
- Author
-
Clayton Lau, Sumanta K. Pal, Yvonne Avila, Avinash Chenam, Jonathan Yamzon, Jaspreet Singh Parihar, Bertram Yuh, and Nora Ruel
- Subjects
Male ,medicine.medical_specialty ,Lymph node positive ,medicine.medical_treatment ,030232 urology & nephrology ,Urology ,Health Informatics ,Disease ,Logistic regression ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Robotic Surgical Procedures ,medicine ,Humans ,Robotic prostatectomy ,Aged ,Retrospective Studies ,Aged, 80 and over ,Prostatectomy ,Salvage Therapy ,business.industry ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Lymph Node Excision ,Surgery ,Lymph Nodes ,Lymph ,business ,Adjuvant - Abstract
Optimal management of node-positive prostate cancer patients after prostatectomy remains a challenge. We evaluated clinically localized patients who demonstrated node positivity and identified predictors for secondary treatment. From 2010 to 2015, clinically localized prostate cancer patients who underwent robot prostatectomy with extended lymphadenectomy and node-positive disease on pathologic analysis were identified. Clinical N1, M1 or salvage cases were excluded. Patients were stratified based on secondary treatments. Kaplan–Meier method was used to determine the time to biochemical and metastatic recurrence. Multivariate logistic regression was used to identify predictors for additional treatment. 145 patients (45 no additional therapy, 47 adjuvant, 53 salvage) had a median follow-up of 31.2 months. Salvage patients had higher median pre-operative prostate-specific antigen (10.8 vs. 9.7 vs. 8.2, p = 0.1), higher percentage of pathologic Gleason ≥8 (50.9 vs. 38.3% and 22.2%, p
- Published
- 2017
- Full Text
- View/download PDF